ABT analyst scorecard · Abbott Laboratories
58 rating actions on ABT in the last 12 months. Of 81 price targets that resolved, 9 were reached while they stood, 66 were replaced by the same firm first, and 6 fell short at their deadline. Ratings: 98% Buy-type, 2% Hold-type, 0% Sell-type. Consensus target $119, 14% above the last close.
Checked through 2026-10-29 · last close $104.11 (2026-10-29). Rebuilt every morning.
The 3 upgrades on ABT came after an average -0.8% move in the 30 days before them.
Firm by firm
| Firm | Latest rating | Date | Latest target | Targets reached | Replaced early | Resolved | Ratings vs sector |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Overweight | 2026-07-17 | $118 | 0 | 4 | 4 | 0 of 1 |
| Evercore ISI Group | Outperform | 2026-07-17 | $120 | 0 | 9 | 9 | 0 of 1 |
| BTIG | Buy | 2026-10-22 | $125 | 0 | 10 | 10 | 0 of 1 |
| Citigroup | Buy | 2026-10-22 | $122 | 0 | 7 | 7 | 0 of 1 |
| TD Cowen | Buy | 2026-10-22 | $118 | 1 | 4 | 5 | — |
| Barclays | Overweight | 2026-10-07 | $120 | 0 | 8 | 8 | 1 of 1 |
| Wells Fargo | Overweight | 2026-10-23 | $120 | 2 | 5 | 7 | 0 of 1 |
| JPMorgan | Overweight | 2026-10-22 | $118 | 0 | 1 | 1 | — |
| Baird | Outperform | 2026-10-22 | $123 | 0 | 1 | 1 | — |
| UBS | Buy | 2026-07-28 | $125 | 0 | 0 | 1 | 0 of 1 |
| Freedom Broker | Buy | 2026-01-29 | $120 | — | — | 0 | — |
| RBC Capital | Outperform | 2026-10-22 | $125 | 2 | 7 | 9 | 0 of 1 |
| Goldman Sachs | Buy | 2026-05-31 | $113 | 1 | 1 | 3 | 0 of 1 |
| Oppenheimer | Outperform | 2026-04-17 | $115 | 1 | 1 | 2 | — |
| Bernstein | Outperform | 2026-01-23 | $125 | 0 | 3 | 3 | 0 of 1 |
| Argus Research | Hold | 2026-10-27 | — | — | — | 0 | — |
| Rothschild & Co | Buy | 2026-10-02 | $127 | — | — | 0 | — |
| Wolfe Research | Outperform | 2026-08-13 | $130 | — | — | 0 | — |
| Benchmark | Buy | 2026-04-17 | $120 | 0 | 1 | 1 | 0 of 1 |
| Bank of America | Buy | 2026-04-17 | $120 | 0 | 0 | 1 | 0 of 1 |
| Stifel | Buy | 2026-04-17 | $120 | 1 | 0 | 2 | 0 of 1 |
Counts for one firm on one stock are small and move together; they are a record, not a grade. Neither the firms nor ABT carry a letter here. Why →
Every call, last 12 months
| Date | Firm | Rating | Action | Price at call | Target | Target status | Move in the 30 days before |
|---|---|---|---|---|---|---|---|
| 2026-10-27 | Argus Research | Buy → Hold | downgrade | $103.10 | — | no target | +1.8% |
| 2026-10-23 | Wells Fargo | Overweight | maintained | $103.70 | $120 | running to 2027-10-23 | +0.2% |
| 2026-10-22 | Citigroup | Buy | maintained | $102.51 | $122 | running to 2027-10-22 | -1.1% |
| 2026-10-22 | RBC Capital | Outperform | maintained | $102.51 | $125 | running to 2027-10-22 | -1.1% |
| 2026-10-22 | Wells Fargo | Overweight | maintained | $102.51 | $119 | replaced 2026-10-23, new $120 | -1.1% |
| 2026-10-22 | JPMorgan | Overweight | maintained | $102.51 | $118 | running to 2027-10-22 | -1.1% |
| 2026-10-22 | TD Cowen | Buy | maintained | $102.51 | $118 | running to 2027-10-22 | -1.1% |
| 2026-10-22 | Baird | Outperform | maintained | $102.51 | $123 | running to 2027-10-22 | -1.1% |
| 2026-10-22 | BTIG | Buy | maintained | $102.51 | $125 | running to 2027-10-22 | -1.1% |
| 2026-10-16 | TD Cowen | Buy | reiterated | $104.89 | $135 | replaced 2026-10-22, new $118 | +2.5% |
| 2026-10-07 | Barclays | Overweight | initiated | $98.73 | $120 | running to 2027-10-07 | -8.9% |
| 2026-10-02 | Rothschild & Co | Neutral → Buy | upgrade | $97.50 | $127 | running to 2027-10-02 | -11.7% |
| 2026-09-08 | TD Cowen | Buy | reiterated | $105.52 | $135 | replaced 2026-10-22, new $118 | -2.1% |
| 2026-08-25 | TD Cowen | Buy | maintained | $116.13 | $135 | replaced 2026-10-22, new $118 | +12.7% |
| 2026-08-21 | TD Cowen | Buy | maintained | $116.64 | $135 | replaced 2026-10-22, new $118 | +16.0% |
| 2026-08-14 | Citigroup | Buy | maintained | $111.25 | $125 | replaced 2026-10-22, new $122 | +24.6% |
| 2026-08-13 | Wolfe Research | Peer Perform → Outperform | upgrade | $111.27 | $130 | running to 2027-08-13 | +25.1% |
| 2026-07-28 | UBS | Buy | maintained | $107.27 | $125 | running to 2027-07-28 | +14.0% |
| 2026-07-17 | Citigroup | Buy | maintained | $100.68 | $112 | replaced 2026-08-14, new $125 | +13.8% |
| 2026-07-17 | Piper Sandler | Overweight | reiterated | $100.68 | $118 | running to 2027-07-17 | +13.8% |
| 2026-07-17 | JPMorgan | Overweight | maintained | $100.68 | $120 | replaced 2026-10-22, new $118 | +13.8% |
| 2026-07-17 | Wells Fargo | Overweight | maintained | $100.68 | $112 | reached 2026-08-18 | +13.8% |
| 2026-07-17 | TD Cowen | Buy | reiterated | $100.68 | $115 | reached 2026-08-21 | +13.8% |
| 2026-07-17 | Evercore ISI Group | Outperform | maintained | $100.68 | $120 | running to 2027-07-17 | +13.8% |
| 2026-07-17 | RBC Capital | Outperform | reiterated | $100.68 | $130 | replaced 2026-10-22, new $125 | +13.8% |
| 2026-07-17 | BTIG | Buy | maintained | $100.68 | $134 | replaced 2026-10-22, new $125 | +13.8% |
| 2026-07-06 | Evercore ISI Group | Outperform | maintained | $95.63 | $112 | replaced 2026-07-17, new $120 | +5.0% |
| 2026-07-01 | Baird | Outperform | initiated | $92.18 | $121 | replaced 2026-10-22, new $123 | +5.0% |
| 2026-06-22 | Piper Sandler | Overweight | reiterated | $87.83 | $115 | replaced 2026-07-17, new $118 | +0.5% |
| 2026-05-31 | Goldman Sachs | Buy | maintained | $87.78 | $113 | reached 2026-08-19 | -1.9% |
| 2026-04-27 | BTIG | Buy | reiterated | $92.80 | $131 | replaced 2026-07-17, new $134 | -10.8% |
| 2026-04-20 | Barclays | Overweight | maintained | $96.00 | $143 | replaced 2026-10-07, new $120 | -9.0% |
| 2026-04-17 | Piper Sandler | Overweight | maintained | $96.81 | $115 | replaced 2026-07-17, new $118 | -10.8% |
| 2026-04-17 | Oppenheimer | Outperform | maintained | $96.81 | $115 | reached 2026-08-21 | -10.8% |
| 2026-04-17 | RBC Capital | Outperform | maintained | $96.81 | $130 | replaced 2026-10-22, new $125 | -10.8% |
| 2026-04-17 | Benchmark | Buy | maintained | $96.81 | $120 | running to 2027-04-17 | -10.8% |
| 2026-04-17 | Evercore ISI Group | Outperform | maintained | $96.81 | $120 | replaced 2026-07-06, new $112 | -10.8% |
| 2026-04-17 | Bank of America | Buy | maintained | $96.81 | $120 | running to 2027-04-17 | -10.8% |
| 2026-04-17 | Stifel | Buy | maintained | $96.81 | $120 | running to 2027-04-17 | -10.8% |
| 2026-04-17 | BTIG | Buy | reiterated | $96.81 | $131 | replaced 2026-07-17, new $134 | -10.8% |
| 2026-04-09 | Goldman Sachs | Buy | maintained | $102.72 | $121 | replaced 2026-05-31, new $113 | -7.1% |
| 2026-04-08 | Barclays | Overweight | maintained | $103.56 | $144 | replaced 2026-04-20, new $143 | -8.1% |
| 2026-04-06 | Evercore ISI Group | Outperform | maintained | $102.30 | $134 | replaced 2026-04-17, new $120 | -6.6% |
| 2026-03-31 | BTIG | Buy | maintained | $102.67 | $131 | replaced 2026-07-17, new $134 | -11.8% |
| 2026-03-11 | Citigroup | Buy | maintained | $110.25 | $136 | replaced 2026-07-17, new $112 | -0.7% |
| 2026-02-02 | Barclays | Overweight | maintained | $109.41 | $142 | replaced 2026-04-08, new $144 | -11.9% |
| 2026-01-29 | Freedom Broker | Hold → Buy | upgrade | $106.09 | $120 | running to 2027-01-29 | -15.7% |
| 2026-01-23 | Citigroup | Buy | maintained | $107.42 | $140 | replaced 2026-03-11, new $136 | -13.9% |
| 2026-01-23 | Bernstein | Outperform | maintained | $107.42 | $125 | running to 2027-01-23 | -13.9% |
| 2026-01-23 | RBC Capital | Outperform | maintained | $107.42 | $135 | replaced 2026-04-17, new $130 | -13.9% |
| 2026-01-23 | Oppenheimer | Outperform | maintained | $107.42 | $132 | replaced 2026-04-17, new $115 | -13.9% |
| 2026-01-23 | Evercore ISI Group | Outperform | maintained | $107.42 | $138 | replaced 2026-04-06, new $134 | -13.9% |
| 2026-01-23 | Piper Sandler | Overweight | maintained | $107.42 | $135 | replaced 2026-04-17, new $115 | -13.9% |
| 2026-01-23 | Wells Fargo | Overweight | maintained | $107.42 | $122 | replaced 2026-07-17, new $112 | -13.9% |
| 2026-01-23 | BTIG | Buy | maintained | $107.42 | $140 | replaced 2026-03-31, new $131 | -13.9% |
| 2026-01-09 | Bernstein | Outperform | maintained | $125.92 | $154 | replaced 2026-01-23, new $125 | +2.8% |
| 2026-01-05 | Barclays | Overweight | maintained | $126.45 | $169 | replaced 2026-02-02, new $142 | +1.1% |
| 2025-11-20 | BTIG | Buy | reiterated | $123.97 | $145 | replaced 2026-01-23, new $140 | — |
Also in Medical Devices
Interactive version with the price chart and target overlay: Scorecard tab on the dashboard. All covered names: index.
How calls are checked
Every call is checked on the firm's own terms. A price target is followed until its own deadline (12 months unless the firm publishes a different horizon) and ends as reached (the stock closed at or beyond it while it stood), replaced (the same firm set a new target first) or short at deadline. A rating is compared with the stock's sector SPDR ETF on total return over the rating's life, because most big-firm ratings are relative: Overweight means "beat its peers", not "go up". Hold-type ratings are tracked, not graded. A firm is numbered only with 30+ resolved targets, and a letter prints only for a firm's whole record where an exact test separates it from a coin flip. None of this is a verdict on anyone's skill, and one day is never a grade. The full method →
Get the daily brief
Our take, the S&P 500 Pulse, the Street's calls and today's docket — one email, weekdays, 9 AM ET, 30 minutes before the open.